Continuing Nivolumab After Melanoma Progression Benefits Some Patients

Source: Medscape

Friday, July 07, 2017 | Medical Studies


Some clinically stable patients with advanced melanoma benefit from continued nivolumab treatment after disease progression, researchers say. Immune checkpoint inhibitors such as nivolumab have atypical response patterns that may not be fully captured by conventional patient response criteria, according to Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center in New York City and colleagues.

Open in New Window

Comments

You must be logged in to leave a comment.